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Edited by Varda RotterAbstract Antiproliferative factor (APF) is a sialoglycopeptide
elevated in the urine of patients with interstitial cystitis, a urinary
bladder disorder of unknown etiology that is characterized by
chronic pelvic pain. The present study was directed toward uncov-
ering a pathway through which APF signals. Treatment of human
urothelial cells with native APF resulted in growth inhibition
accompanied by blockade of cell cycle transit and increased
p53. Reduced expression of p53 by RNA interference diminished,
while ectopic expression of p53 mimicked, the eﬀects of APF.
These are the ﬁrst ﬁndings implicating the network of p53 target
genes in urothelial defects associated with interstitial cystitis.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Interstitial cystitis (IC) is a chronic bladder disorder with
long-term symptoms of pelvic and or perineal pain, thinning
or ulceration of the bladder epithelial lining, urinary fre-
quency, and urgency. IC patients are generally diagnosed by
the presence of certain clinical criteria in the absence of other
identiﬁable causes for the symptoms (e.g., urinary tract infec-
tion). Although, there are multiple hypotheses about the pri-
mary cause of IC, the underlying molecular mechanism of
IC remains completely undeﬁned [1].
Three urine biomarkers for IC have been identiﬁed in pub-
lished reports: the EGFR/ErbB1 peptide ligands, heparin-bind-
ing epidermal growth factor-like growth factor (HB-EGF), and
epidermal growth factor (EGF) [2–4], and a novel sialoglyco-
peptide, named antiproliferative factor (APF) [3,4]. HB-EGF
and EGF are present under normal conditions in human urine,
but their concentration varies in a statistically signiﬁcant and
inverse manner (EGF levels are higher and HB-EGF levelsAbbreviations: APF, antiproliferative factor; EGF, epidermal growth
factor; FBS, fetal bovine serum; HB-EGF, heparin-binding epidermal
growth factor-like growth factor; IC, interstitial cystitis; MTT, 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
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doi:10.1016/j.febslet.2007.06.058are lower) in patients with IC as compared to their age-, race-
and gender-matched controls [4]. APF, a low molecular weight,
glycosylated peptide related to the membrane receptor frizzled-
8, was puriﬁed from the urine of IC patients [5]. Bioactivities
attributed to APF include: suppression of urothelial cell prolif-
eration; increases in transcellular permeability; lowering of
the expression of proteins that form intercellular junctional
complexes; and reduction in the production of HB-EGF from
urothelial cells [2,4,6–9]. APF/antiproliferative activity is
detectable in the urine of approximately 95% of IC patients
(as compared to approximately 9% of controls) [2–4]. This
accumulation in urine of a bioactive factor, capable of altering
the behavior of urothelial cells, is consistent with the clinical
observation of epithelial thinning and denudation observed in
IC bladder tissue [10,11].
The cell cycle regulatory protein, p53, is an essential media-
tor of cell cycle transit, apoptotic cell death, and cellular re-
sponses to stress [12,13]. p53 is a transcription factor that
controls the expression of numerous genes in a network that
is presently being deﬁned using multiple approaches. In re-
sponse to stressful environmental conditions, p53 protein lev-
els rise, leading to cell cycle arrest or apoptosis. Loss of p53
function by mutation has been found to be the most common
genetic alteration observed in human cancer cells, implying
p53 as a suppressor of hyper-proliferation [12,13].
Because of its atypical features, the signaling mechanisms by
which APF induces its anti-proliferative activity are of consid-
erable interest. We show here that treatment of normal human
urothelial cells, and T24 human bladder carcinoma cells, with
APF increases p53 levels and that experimentally induced
changes in p53 levels alter the APF eﬀect on cell growth, indi-
cating that p53 is involved in the mechanism of APF-induced
growth suppression observed in the context of IC.2. Materials and methods
APF was puriﬁed from the supernatant of bladder epithelial cells ex-
planted from one IC patient [6]. Mock APF was prepared using the
supernatant of bladder epithelial cells from a normal control and the
same puriﬁcation procedure. Small interfering RNAs (siRNAs) and
Abs against p53 were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA).
2.1. Cell culture and transfection
Human urothelial cells derived from bladder biopsies and speciﬁc
growth medium were obtained from Oligene (Berlin, Germany). T24
cells (ATCC HTB4) were cultured in McCoy’s 5A containing 10% fetalblished by Elsevier B.V. All rights reserved.
Fig. 1. APF eﬀect on cell proliferation and cell cycle progression. (A)
Human urothelial cells were incubated in media containing 10 ng/ml
APF or Mock APF control. At the indicated time points, cell number
was counted by MTT assay. (B) FACS analysis was performed to
determine the cell cycle transit 48 h after treatment.
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solution (all from Sigma) at 37 C/5% CO2 condition. T24 cells were
transiently transfected with expression plasmids using Lipofectamine
2000 (Invitrogen, Carlsbad, CA).
2.2. Construction of wild type p53 plasmid
For expression of p53 with C-terminal HA-tag, pCMV-Tag4B
(Stratagene) was used after modiﬁcation. Oligonucleotides containing
HA-tag encoding sequences and overhangs compatible with the XhoI
and KpnI restriction sites (sense; 5 0-tcgagTACCCATACGACGTCC-
CAGACTACGCTTAGtac, antisense; 5 0-taAGCGTAGTCTGG-
GACGTCGTATGGGTAc) were used for pCHAb construct. The
coding region of p53 was ampliﬁed by PCR using 5 0 sense primer con-
taining a NotI restriction site (5 0-gatcgcggccgccATGGAGGAG-
CCGCAGTCA) and 3 0 antisense primer containing the XhoI
restriction site (5 0-gatcctcgagGTCTGAGTCAGGCCCTTC), and
pGBKT7-53 (BD-Clontech) as template was then inserted into the
NotI and XhoI restriction sites of pCHAb (pCHAb-p53).
2.3. Cell proliferation assay
Cells were plated onto 24-well tissue culture plates in standard
growth medium as described above at a density of 1 · 104 cells/
well. After 12 h serum starvation, APF or Mock APF was added to
the medium, and cells were incubated for the additional time indi-
cated. Viable cell number was determined by uptake of 3-(4,5-dimeth-
ylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) as described
[14].
2.4. Cell cycle analysis by FACS
Cells were treated with puriﬁed APF or Mock APF for the indicated
times. After ﬁxing and staining with propidium iodide, they were visu-
alized by ﬂow cytometry [14].
2.5. Indirect immunoﬂuorescence microscopy
Cells were treated with puriﬁed APF or Mock APF for 7 d, ﬁxed
with 3% paraformaldehyde and incubated with anti-p53 or anti-
GAPDH Abs in 1% BSA/PBS solution, followed by species-speciﬁc
secondary antibodies conjugated to Texas-Red ﬂuorophores. Slides
were mounted in Vectashield mounting medium containing DAPI
(Vector Laboratories, Inc., Burlingame, CA) and analyzed with oil
immersion objectives using a LSM 510 META NLO laser scanning
confocal microscope (Carl Zeiss MicroImaging, Inc. Thornwood,
NY).
2.6. Western blot analysis
Cells were solubilized with lysis buﬀer [1% Nonidet P-40; 50 mM
Tris, pH 7.4; 10 mMNaCl; 1 mMNaF; 5 mMMgCl2; 0.1 mM EDTA;
1 mM PMSF; and COMPLETE protease inhibitor cocktail tablet
(Roche Diagnostocs Corp.)] and centrifuged at 12000 · g for 15 min.
The supernatant was assayed for protein concentration determination
and equal amounts of protein were used for Western blotting.
2.7. Statistical analysis
Data were compared using a paired Student’s t-test. P-values <0.05
were considered signiﬁcant.3. Results
3.1. APF suppresses human urothelial cell proliferation and cell
cycle transit
APF was previously demonstrated to inhibit cell prolifera-
tion and arrest the cell cycle of explanted primary normal hu-
man bladder cells [6]. We conﬁrmed the inhibitory eﬀect of
APF on cell growth using early passage (<6 passages) urothe-
lial cells derived from human bladder tissues obtained from
surgical biopsies. Proliferation rate was signiﬁcantly decreased
in the presence of APF as compared to Mock APF (Fig. 1A).
Similarly, treatment of urothelial cells with APF increased the
G2/M cell number as measured by FACS analysis (Fig. 1B),demonstrating that APF appears to block cell cycle transit pre-
dominantly at the G2/M boundary of primary urothelial cells.
Mock APF did not show anti-proliferative activity.
3.2. p53 mediates APF eﬀect
The identiﬁcation of p53 as a downstream mediator of the
eﬀects of APF provides support for the hypothesis that cell cy-
cle modulation may be a factor in IC. While the p53 protein
expression level increased following APF treatment
(Fig. 2A), the level of GAPDH was not changed (data not
shown). Consistent with these data, immunoﬂuorescence (IF)
staining demonstrated increased p53 levels following treatment
with APF as compared to Mock APF (Fig. 2B).
In subsequent experiments, we assessed whether a high p53
level is associated with biological functions of the APF peptide
using RNA interference to lower p53 expression in urothelial
cells. When p53 protein expression was decreased experimen-
tally by transfection with p53 small inhibitory RNA (siRNA)
duplexes, the inhibitory eﬀect of puriﬁed native APF on cell
growth was partially reversed (Fig. 3). APF exposure increased
expression of p53 and its target, p21Cip1/WAF1, a cyclin-
dependent kinase (CDK) inhibitor [15]. Down-regulation of
p53 eliminated the induction in p21Cip1/WAF1 protein level
even in the presence of APF.
3.3. APF peptide inhibits growth of T24 bladder cells
To expand our observations to another bladder cell type,
and to avoid the limitations associated with primary cell cul-
tures, we performed similar experiments to assess the eﬀect
of APF on cell growth using T24 bladder cancer cells. This cell
line was chosen because of its human urothelial origin and be-
cause it responds to the antiproliferative eﬀect of APF in a sim-
ilar fashion to primary bladder urothelial cells [6]. As shown in
Fig. 4A, APF treatment of serum-starved T24 cells led to
growth suppression by about 40% in comparison to treatment
with the Mock control (P < 0.05). In addition, there was a sig-
Fig. 3. Reversal of the APF eﬀect by p53 knockdown. Urothelial cells
were transiently transfected with p53 siRNA duplex and incubated in
media containing 10 ng/ml APF or Mock APF (control) for 7 days.
Cell number was determined by MTT analysis. The protein levels of
p53 and p21Cip1/WAF1 under individual experimental conditions
were determined by Western blot.Fig. 2. Increased p53 protein expression in response to APF. (A)
Whole cell lysates were prepared from urothelial cells treated with
10 ng/ml APF or Mock APF for 7 d. Western blot analysis was
performed using anti-p53 and GAPDH Abs. (B) Cells were stained
with anti-p53 Ab (red), and nuclei were counterstained with DAPI
(blue).
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cells (Fig. 4B).
3.4. Over-expression of p53 inhibits cell proliferation in Mock
APF-treated cells
To investigate whether p53 mediates the APF eﬀect on cell
growth, we attempted to alter intracellular p53 protein levels.
T24 cells were transfected with vector only or vector contain-
ing a p53 expression construct and incubated with puriﬁed
APF or Mock APF-containing serum free medium. Fig. 5A
shows that incubation with APF suppressed the proliferation
of cells transfected with vector alone (‘‘APF’’), compared toFig. 4. Inhibition of T24 bladder cancer cell growth by APF. (A) T24 cell
(control), followed by cell number determination by MTT assay at the indica
or Mock APF in the presence of serum. Three days later, FACS analysis waMock APF treatment of the same cells. While p53 over-expres-
sion inhibited the proliferation of Mock APF-treated cells,
there was no signiﬁcant diﬀerence in growth inhibition when
p53 and APF were used together. Western blotting assessment
of p53 levels under the diﬀerent conditions showed that, as
anticipated, p53 accumulated with both APF treatment and
p53 over-expression. However, ectopic expression of p53 did
not signiﬁcantly elevate the p53 level beyond that induced by
APF in T24-p53 cells.
To test directly whether p53 contributes to APF-induced
growth arrest in T24 cells, we examined whether siRNA
knockdown of p53 expression aﬀected the response of T24 cells
to APF. p53 levels were assessed in cell lysates collected after
puriﬁed APF or Mock APF treatment in the presence of con-
trol siRNA or p53 siRNA. As shown in Fig. 5B, knock down
of p53 using interfering RNA signiﬁcantly attenuated the
growth arrest elicited by APF.s were serum-starved and treated with 10 ng/ml APF or Mock APF
ted time points. (B) Serum-starved T24 cells were stimulated with APF
s performed to assess the cell cycle.
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Fig. 5. Eﬀects of altered p53 level. (A) T24 cells were transiently transfected with p53 or vector only. Cell counting was performed 7 days after
treatment by MTT assay. p53 levels were determined by Western blotting. (B) p53 in T24 cells was knocked down using siRNA. Following 10 ng/ml
APF or Mock APF treatment for 7 d, the cells were counted, and p53 and p21Cip1/WAF1 protein levels were assessed.
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In this study, we identiﬁed p53 as an important mediator of
APF-induced eﬀects on bladder epithelial cells. Several lines of
evidence support this conclusion: (1) APF treatment sup-
pressed cell proliferation by cell cycle arrest of human bladder
urothelial cells; (2) p53 levels increased signiﬁcantly following
APF stimulation; (3) p53 down-regulation enhanced the sup-
pressive eﬀect of APF on cell growth; and (4) over-expression
of p53 itself induced cell cycle arrest in the absence of APF.
These observations indicate that p53 can function as a cell cy-
cle regulator of human urothelial cells of bladder origin.
The ﬁnding that p53 is involved in the mechanism of action
of APF will now allow detailed mechanistic studies of the ef-
fects of APF on cells. Several avenues of investigation are war-
ranted based on our present results. The activated proteasome
degrades several proteins involved in cell cycle control, includ-
ing p53. Thus, it is possible that stabilization of p53 levels fol-
lowing APF exposure results in transcriptional activation of
proteins involved in cell cycle control. The stability of p53 is
also inﬂuenced by a number of p53-interacting proteins,
including the p53-associated factor, HAUSP [16,17], the hom-
edomain-interacting protein kinase 2 (HIPK2) [18], kinases
such as ataxia-telangiectasia mutated (ATM) [19–21] and
ATR (ATM and Rad3-related) [22,23], and the nuclear ribo-
nucleoprotein K (hnRNP K), an Mdm2 target and p53 tran-
scriptional co-activator [24,25]. Phosphorylation of p53 is
known to protect the protein from degradation via Mdm2
ubiquitin ligase-dependent mechanisms [13,26–31]. Although
these and other aspects of the p53 regulatory network have
been described, the molecular mechanisms linked to p53 in
the context of IC have not been determined and additional
studies on the p53 signaling pathway and of the p53 modiﬁca-
tion status in response to APF remain to be investigated.
A chronic bladder disorder, IC aﬀects more than 1 million
Americans. Although medical treatments and procedures, suchas bladder instillation, hydrodistension, and the pharmaceuti-
cal drugs are prescribed for those aﬄicted with the disease,
these treatments are eﬀective in only a small percentage of pa-
tients with undesirable side eﬀects. We have described in this
paper the novel ﬁnding that exposure of bladder urothelial
cells to APF, a urinary glycopeptide biomarker of IC, results
in increased p53 protein expression and that p53 is a mediator
of cell cycle arrest induced by APF. These data suggest the
possibility of targeting p53, or p53 signaling network proteins,
as a means of abrogating the pathologic eﬀects of urinary
APF, and new options for therapeutic intervention in IC seen
clinically.
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